Remimazolam: short-acting anesthetic. Ph 3 study in procedural sedation in US. Safety data in ASA III/IV patients in Ph 3 colonoscopy study and Ph 3 bronchoscopy study. US filing exp by partner Cosmo Pharmaceuticals in 4Q18/1Q19. Initiated Ph 3 in general anesthesia in EU in July 2018, exp completion 2019. Favorable safety profile of midazolam and attractive half-life of propofol: best of both industry standards.
Central Nervous System, Pain
Biotechnology, Specialty Pharmaceutical
100MM - 500MM
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by